From zhuiastate.edu  Mon Apr 29 18:27:12 2013
From: "Hu, Zhiliang [AN S]" <zhuiastate.edu>
To: Multiple Recipients of <epigroupanimalgenome.org>
Subject: FW: Targeting BET Bromodomains and HDACs: View two preliminary
 meeting agendas
Date: Mon, 29 Apr 2013 18:27:12 -0500

.From: Epigenetic Targets and Therapies Events [olgaphealthtech.com]  
.Sent: Monday, April 29, 2013 4:30 PM  
.Subject: Targeting BET Bromodomains and HDACs: View two preliminary meeting 
  agendas 

11th Annual https://chidb.com/register/2013/dot/reg.asp September 24-26,
2013 | Westin Waterfront | Boston, Massachusetts

Preliminary Agendas for Two Back-to-Back Programs

Targeting Epigenetic Readers: Inhibiting Chromatin Readers - from
Bromodomains to Beyond

September 24-25, 2013

The expanse of epigenetic modulators poised as promising therapeutic
targets has never been more robust. Yet, until recently, enzymatic
modulators of writer and eraser classes have been the main focus of
therapeutic development. Over the past few years, a relatively
underexplored group of proteins have emerged as promising targets.
Operating at the interface of translating histone marks, proteins such as
the BET family bromodomain readers have demonstrated favorable activity
when inhibited in human cancers. Therapeutic potential is evident, but with
little potent and selective chemical matter available for inhibition, the
biological consequence associated with disrupting epigenetic reading is
largely undefined. Cambridge Healthtech Institute is proud to announce the
Inaugural Targeting Epigenetic Readers
(http://www.discoveryontarget.com/Epigenetic-Readers/) conference, designed
to unite academic and industry researchers for the development of chemical
probes to further our understanding of the therapeutic opportunities
associated with targeting reader domains.

FEATURED OPENING SESSION: LEADERS IN EPIGENETIC DRUG DISCOVERY

>> FEATURED PRESENTATION: 
Peter J. Tummino, Ph.D., Head, Biology, Cancer Epigenetics Discovery 
Performance Unit, Oncology R&D, GlaxoSmithKline Pharmaceuticals  

>> FEATURED PRESENTATION: 
Cheryl H. Arrowsmith, Ph.D., Chief Scientist, Structural Genomics Consortium; 
Professor, Medical Biophysics; Canada Research Chair, Structural Proteomics, 
University of Toronto 

THERAPEUTIC APPLICATIONS OF INHIBITING BET BROMODOMAINS

Talk Title to be Announced Kimberly Stegmaier, M.D., Assistant Professor,
Department of Pediatrics, Harvard Medical School; Independent Investigator,
Pediatric Oncology, Dana-Farber Cancer Institute; Attending Physician,
Children's Hospital Boston; Associate Member, Broad Institute of Harvard
and MIT
  
Bromodomain Inhibition as a Novel Therapeutic Treatment for Pulmonary 
Fibrosis David C. Budd, Ph.D., Honorary Lecturer, Department of Inflammation, 
Center for Rheumatology & Connective Tissue Diseases, University College 
London Medical School 

BET Proteins as Critical Links between Chronic Inflammation, 
Insulin-Resistant Obesity and Certain Cancers Gerald V. Denis, Ph.D., 
Associate Professor, Cancer Research Center, Department of Pharmacology & 
Medicine, Boston University School of Medicine 

Mechanisms of BET Bromodomain Inhibition in the Control of Gene Expression 
Robert J. Sims III, Ph.D., Senior Director of Biology, Constellation 
Pharmaceuticals, Inc. 
  
Identification of Potent, BET Bromodomain Inhibitors for Treatment of Cancers 
Hosahalli Subramanya, Ph.D., Senior Vice President, Structural Biology & Lead 
Generation, Aurigene Discovery Technologies, Ltd. 

MECHANISTIC INSIGHTS INTO READER-INDUCED TUMORIGENESIS

Targeting Bromodomains in NUT Midline Carcinoma Christopher A. French,
M.D., Assistant Professor, Department of Pathology, Harvard Medical School;
Assistant Professor, Pathology, Brigham And Women's Hospital
  
CHD5 and H3: A Must-Read for Tumor Suppression 
Alea A. Mills, Ph.D., Professor & Team Leader, Cold Spring Harbor Laboratory 
  
Talk Title to be Announced 
John Trzupek, Ph.D., MBA, Principal Scientist, Biotherapeutics, External 
Chemistry Innovation, Pfizer 

PROGRESS TOWARDS NOVEL CHEMICAL READER ANTAGONISTS

From Epigenetic Mechanism to Targeted Therapy Ming-Ming Zhou, Ph.D., Harold
and Golden Lamport Professor and Chairman, Department of Structural &
Chemical Biology; Co-Director, Experimental Therapeutics Institute, Icahn
School of Medicine at Mount Sinai
  
Promoting Illiteracy: Inhibition of Methyl-Lysine Readers by Small Molecule 
Chemical Probes Lindsey Ingerman James, Ph.D., Research Assistant Professor, 
Center for Integrative Chemical Biology & Drug Discovery Division of Chemical 
Biology and Medicinal Chemistry Eshelman School of Pharmacy; Visiting 
Scientist, Chemical Biology, GlaxoSmithKline, Research Triangle Park 
  
Disrupting the Reader 
John M. Denu, Ph.D., Director, Epigenetics Theme, Wisconsin Institute for 
Discovery; Professor, Biomolecular Chemistry, School of Medicine and Public 
Health, University of Wisconsin 
  
Histone Binding Mechanisms and Specificities of PHD Fingers 
Tatiana Kutateladze, Ph.D., Associate Professor, Department of Pharmacology, 
Anschutz Medical Campus, University of Colorado 

--------------------------------------------------------- 
Next Generation Histone Deacetylase Inhibitors: 
Targeting HDACs for Oncology, Inflammation, Neurodegeneration, Diabetes and 
Other Indications 

September 25-26, 2013

HDACi were primarily developed as anti-tumor agents for cancer, but many
are now being explored for treating neurodegenerative, immunologic,
metabolic, inflammatory and cardiovascular disorders. However, much remains
to be elucidated about the functional implications of modulating HDACs and
understanding the signaling pathways that can cause adverse cellular
effects and unwanted toxicity. Cambridge Healthtech Institute's Seventh
Annual conference on Next Generation Histone Deacetylase Inhibitors, tracks
both the scientific and clinical progress being made to better understand
the cellular function of this complex drug target family.

DESIGNING THE IDEAL INHIBITOR

Talk Title to be Announced James E. Bradner, M.D., Assistant Professor,
Department of Medicine, Harvard Medical School; Investigator, Department of
Medical Oncology, Dana-Farber Cancer Institute

Sirtuins in Aging and Disease Leonard P. Guarente, Ph.D., Novartis
Professor of Biology, Harvard University

Chemogenomic Approaches to Spatiotemporal Regulation of HDAC Activity Ralph
Mazitschek, Ph.D., Assistant Professor, Center for Systems Biology,
Chemical Biology Platform, Massachusetts General Hospital

Novel Lysine Acylation Pathways and Acetylation-Independent Mechanisms of
HDACs Yingming Zhao, Ph.D., Professor, The Ben May Department for Cancer
Research, University of Chicago

HDACI FOR CARDIOVASCULAR INDICATIONS

HDAC Inhibitors for the Treatment of Pathological Muscle Remodeling Timothy
A. McKinsey, Ph.D., Associate Professor and Associate Division Head for
Translational Research, Department of Medicine, Division of Cardiology,
University of Colorado Denver

HDAC Inhibition to Target Heart Disease Joseph Hill, M.D., Ph.D.,
Professor, Internal Medicine and Molecular Biology, Chief of Cardiology,
University of Texas Southwestern Medical Center; Director, Harry S. Moss
Heart Center

HDAC Inhibition and Cardiac Protection Ting Zhao, M.D., Associate
Professor, Department of Surgery, Roger Williams Medical Center, Boston
University Medical School

HDACI FOR CNS INDICATIONS

HDACi in the Treatment of Muscular Dystrophies: Targeting Cellular and
Molecular Networks that Control Muscle Repair Puri Pier Lorenzo, M.D.,
Ph.D., IRCCS Fondazione Santa Lucia, Pharmacology and Epigenetics, Rome,
Italy; Associate Professor, Sanford-Burnham Institute for Medical Research

HDACI FOR TARGETING METABOLIC DISORDERS

Design of Class I Isoform Selective Inhibitors for Use in Non-Oncology
Indications Edward Holson, Ph.D., Director, Medicinal Chemistry, Stanley
Center for Psychiatric Research, The Broad Institute of MIT and Harvard

Inhibition of HDAC3 Protects Beta-Cell Function Bridget K. Wagner, Ph.D.,
Director, Pancreatic Cell Biology, Chemical Biology Program, The Broad
Institute of MIT and Harvard

-------------------------------------------------------- 
Recommended Short Courses*  

Monday, September 23

12:00 - 3:00 pm: Biochemical and Structure-Based Approaches to Epigenetic
Drug Discovery

3:30 - 6:30 pm: Characterization and Quantification of Histone
Modifications

Wednesday, September 25

6:45 - 9:30 pm: Tools for Detection and Utilization of Epigenetic Markers

Registration information https://chidb.com/register/2013/dot/reg.asp

* Separate registration is required 

Epigenetic Targets and Therapies programs at Discovery on Target 2013:

http://www.discoveryontarget.com/KinaseInhibitorPipeline/ September 24-25,
2013
  
 
FOR SPONSORSHIP AND EXHIBIT INFORMATION, CONTACT:  
Jon Stroup 
Manager, Business Development 
781-972-5483 
jstrouphealthtech.com   

Cambridge Healthtech Institute, 250 First Avenue, Suite 300, Needham, MA
02494 P: 781.972.5400 | F: 781.972.5425 | healthtech.com